Skip to content
Review Open access

Artificial Intelligence and Multimodal Data Approaches for Diagnosis, Prognosis, and Treatment Decision Support in Diffuse Large B-Cell Lymphoma and Acute Myeloid Leukaemia: A Systematic Review

Sep 2026 · Journal of Advances in Medical and Pharmaceutical Sciences · Vol 28, pp. 1-19 · 0 citations

TL;DR

Artificial intelligence and multimodal data approaches show greatest maturity for prognostic stratification, but diagnostic replacement and treatment selection remain unproven.

Abstract

Aims: To synthesise and critically appraise evidence on artificial intelligence (AI) and multimodal data approaches for diagnosis, prognosis, and treatment decision support in diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukaemia (AML), and to compare how disease biology shapes model design and clinical readiness. Study Design: Systematic review with narrative synthesis. Place and Duration of Study: PubMed/MEDLINE, Embase, Scopus, Web of Science Core Collection, IEEE Xplore, and the Cochrane Library were searched from database inception to 29 July 2026. Methodology: English-language original studies involving human participants, clinical images, human-derived samples, or patient-derived datasets were eligible. Two reviewers independently screened records, assessed full texts, and extracted study characteristics, data modalities, analytical methods, validation approaches, and performance measures. PROBAST+AI domains were used to guide appraisal of eligible patient-level prediction models; exploratory multi-omics, molecular-subtyping, biomarker-discovery, and segmentation studies underwent structured descriptive appraisal. TRIPOD+AI informed assessment of reporting completeness. Owing to substantial clinical and methodological heterogeneity, findings were synthesised narratively. Results: Twenty-eight studies were included: 22 on DLBCL and six on AML. DLBCL research was dominated by PET/CT radiomics, deep imaging, digital pathology, and imaging-clinical-molecular fusion. Internally evaluated diagnostic models reported area under the curve values as high as 0.999, whereas externally validated prognostic models achieved values of 0.66-0.71 and showed inconsistent incremental improvement over the International Prognostic Index. AML studies mainly integrated genomic, transcriptomic, epigenomic, single-cell, proteomic, metabolic, and functional drug-response data. Prognostic models reported concordance indices of 0.72-0.81 and time-dependent area under the curve values of 0.795-0.899. The most frequent methodological concerns were retrospective sampling, high-dimensional modelling in modest cohorts, incomplete calibration reporting, and limited independent validation. Treatment-response models in both diseases remained retrospective or exploratory, and none demonstrated improved outcomes through AI-guided treatment allocation. Conclusion: AI and multimodal data approaches show greatest maturity for prognostic stratification, but diagnostic replacement and treatment selection remain unproven. Prospective, multicentre clinical-impact validation is the principal requirement for translation into routine care.

Read PDF

Similar papers

Review Open access Sep 2026

Artificial intelligence and computational prediction models for risk stratification, treatment response, and outcomes in colorectal cancer: a narrative review

A decision-centred synthesis indicates that CRC AI is most mature as site-specific and task-specific reader assistance or triage rather than autonomous decision-making.

Wen-Neng Liu, Dan Zhang, Chun Dang et al. · 0 citations
Review Open access Jul 2026

Artificial Intelligence Decision-Making in Multidisciplinary Tumor Boards for Head and Neck Cancer: A Systematic Review.

IMPORTANCE Artificial intelligence (AI) is increasingly integrated into clinical decision-making, including applications in pathology, radiomics, and multidisciplinary tumor boards (MDT) for head and neck (ENT) cancer. However, the current scope and performance of AI tools within MDT settings remain unclear. OBJECTIV...

Karl Bouchard-Locat, Vincent Raby, A. Christopoulos et al. · 0 citations
Review Open access Oct 2026

Artificial Intelligence in Gastric Cancer: Diagnostic, Prognostic, and Predictive Developments, Evidence Maturity, and Translational Challenges

ABSTRACT Background Gastric cancer (GC) remains a major global health burden characterized by substantial heterogeneity in diagnosis, prognosis, and treatment response. Artificial intelligence (AI), including machine learning (ML) and deep learning (DL), has been increasingly investigated for the analysis of endoscopic...

Chong Chen, Wei-Song Xu, Tong-Le Wu et al. · 0 citations
Review Open access Oct 2026

Artificial Intelligence Classification Algorithms for Leukaemia Diagnosis: A Structured Review of Model Performance and Clinical Readiness

Leukaemia diagnosis and classification increasingly combine morphology with immunophenotypic, cytogenetic and molecular information, while artificial intelligence (AI) offers a potential means of standardising image-based assessment and reducing repetitive workload. This structured review critically examines contempora...

Okwedi Kelicha, A. C. Eberendu, C. Nwokorie · 0 citations
Review Open access Oct 2026

Prognostic Evidence for Artificial Intelligence-Derived PET Tumour-Burden Biomarkers in Cancer: A Systematic Review

Background/Objectives: Artificial intelligence (AI) can automate tumour-burden measurement on positron emission tomography (PET), including metabolic tumour volume (MTV) and total metabolic tumour volume (TMTV). This review evaluated prognostic evidence for AI-derived PET tumour-burden biomarkers, particularly comparis...

S. Byun, Yunhwi Hwang, H. Kim et al. · 0 citations
Review Open access Sep 2026

Integrated Multi-Modal Risk Stratification Outperforms Single-Biomarker Testing in Predicting Frontline Therapy Failure in Diffuse Large B-Cell Lymphoma: A Narrative Review of the Evidence for Decision-Point-Anchored Molecular Scoring

Abstract Background: Diffuse Large B-Cell Lymphoma is a classification of non-Hodgkins lymphoma cancers. DLBCL is extremely difficult to consistently treat because of its heterogeneity, meaning treatment must be precise and tailored. Some methods of determining prognoses and care include the IPI, COO, Single-biomarker...

Malaika Koreshi, E. Engh, Suhas Kundurthi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.